Compare MGNI & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGNI | PGEN |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | United States | United States |
| Employees | 514 | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2014 | 2013 |
| Metric | MGNI | PGEN |
|---|---|---|
| Price | $12.11 | $4.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $25.22 | $8.33 |
| AVG Volume (30 Days) | 1.7M | ★ 5.2M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 493.75 | N/A |
| EPS | ★ 0.95 | N/A |
| Revenue | $156,414,000.00 | ★ $230,981,000.00 |
| Revenue This Year | $6.33 | $1,115.92 |
| Revenue Next Year | $9.73 | $81.04 |
| P/E Ratio | $12.67 | ★ N/A |
| Revenue Growth | ★ 25.45 | N/A |
| 52 Week Low | $9.29 | $1.23 |
| 52 Week High | $26.65 | $5.47 |
| Indicator | MGNI | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 46.47 | 57.90 |
| Support Level | $11.81 | $4.02 |
| Resistance Level | $14.48 | $4.44 |
| Average True Range (ATR) | 0.51 | 0.32 |
| MACD | 0.04 | 0.12 |
| Stochastic Oscillator | 45.24 | 83.08 |
Magnite is a supply-side advertising platform that provides technology and yield management solutions to content publishers, enabling them to monetize their digital advertising inventory. Magnite receives a percentage of all advertising inventory that it sells. 43% of Magnite's revenue is derived from connected television, or CTV, streaming platforms, 40% from mobile applications, and the remainder from general websites. Beyond the typical monetization responsibilities inherent to an SSP, Magnite also provides upstream advertising servers to CTV publishers, allowing them to have granular control over direct-sold, programmatic guaranteed, and open-auction logic. Magnite competes with other independent SSPs, supply path optimization solutions, and closed ecosystems like Meta.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.